Market Research Report
Gene Therapy Market with COVID-19 Impact Analysis, By Indication, By Vector Type, and By Region - Size, Share, & Forecast from 2021-2027
|Gene Therapy Market with COVID-19 Impact Analysis, By Indication, By Vector Type, and By Region - Size, Share, & Forecast from 2021-2027|
Published: March 1, 2021
AnalystView Market Insights
Content info: 331 Pages
Delivery time: 2-3 business days
The global Gene Therapy market was valued at USD 2.36 billion in 2020, growing with 21.7 CAGR during the forecast period, 2021-2027.
Gene therapy is a method in which DNA or gene is introduced into a patient for treating genetic diseases. Gene therapy involves repressing, repairing, or replacing dysfunctional genes that cause disease. This therapy is used for the treatment of some genetic diseases such as cystic fibrosis, and muscular dystrophy as well as various inherited disorders, and cancer.
The gene therapy market is estimated to witness a substantial growth rate in the next few years. The increasing demand for advanced therapies and gene delivery technology is boosting the market growth. In addition, several market players are engaging in commercializing their therapy products. However, the ongoing COVID-19 pandemic has impacted the research procedures in gene therapies. According to the Office of Tissues & Advanced Therapy in the U.S. FDA, there is no increase in the new drugs application & therapies due to COVID-19. Further, the high cost associated with therapy development may restrain the market growth.
Furthermore, the growing adoption of payment models like health outcome-based and financial-based agreements is boosting the therapies market growth. The cell and gene therapy sector has been impacted by the SARS COV-2 pandemic. Various research & enrollment processes and universities had been shut down thus, clinical trials progress is also slow. On the other hand, pharma companies are collaborating with CMOs to remain competent in the market. For example, in 2020, Univercells has unveiled Exothera, a viral vector CDMO that serves cell & gene therapy developers.
The gene therapy market is segregated into indication and vector type segments. Based on indication, the Spinal Muscular Atrophy (SMA) segment held the largest revenue share of over 40.0% in 2019. By vector type, the AAV type segment is projected to offer potential growth opportunities for the market during the forecast period.
In 2019, North America held the largest revenue share of over 50.0% in the overall market. With the presence of a large number of pharma companies and a rising focus on R&D development, FDA approvals are boosting regional growth. Europe is projected to expand at a significant rate over the forecast period. The companies in the European market are seeking FDA approval as well after EU approvals to gain traction in the global industry. The Asia Pacific is projected to offer lucrative growth opportunities over the forecast period, 2021 to 2027.
The gene therapy market is moderately competitive in nature. Top players in the market indulge in advancements in gene therapies to enhance their global reach. Key players in the industry include REGENXBIO, Inc., Oxford BioMedica plc, Dimension Therapeutics, Inc., and Bristol-Myers Squibb Company. These players in the market engage in strategic activities such as collaboration, and new product developments to maintain their position in the market. For example, in 2020, REGENXBIO Inc., has collaborated with Ultragenyx Pharmaceutical Inc. for using NAV technology platforms.
Key features of the study:
This proposed research study on Gene Therapy market provides market size (US$ million), compound annual growth rate (CAGR %) and forecast estimation (2020-2027), considering 2019 as the base year
The research report elucidates potential growth opportunities across different segments/countries and explains attractive investment proposition matrix for Gene Therapy market
The overall report identifies new investment opportunities, challenges faced by established players, and growth factors to sustain in the Gene Therapy market
Impact of COVID-19 on Gene Therapy market size, forecast, CAGR, and market dynamics are discussed in detail under the research scope. Detailed insight on Gene Therapy market post-COVID will also be covered.
In order to give the users of this report a comprehensive view on the Gene Therapy market, we have also included competitive landscape and key innovator analysis for the Gene Therapy market.
The study encompasses a growth prospect mapping analysis, wherein all the industry segments are benchmarked based on their market size, growth rate and end-user's attractiveness.
The report offers detailed company profiling featuring major market participants which will help users to understand their financial information and strategic initiatives of players operating in the Gene Therapy market.
In addition, the report also unveil the important acquisitions & mergers, collaborations & joint ventures, new product launch, research & development, regional expansion of major participants involved in the Gene Therapy market on global as well as regional level.
The global Gene Therapy market report primarily caters to various stakeholders in this industry including suppliers, investors, new entrants, distributors, and financial analysts
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL GENE THERAPY MARKET KEY PLAYERS
Oxford BioMedica plc
Dimension Therapeutics, Inc.
Bristol-Myers Squibb Company
Applied Genetic Technologies Corporation
F. Hoffmann-La Roche Ltd.
Bluebird Bio, Inc.
Gilead Lifesciences, Inc.
Benitec Biopharma Ltd.
Gensight Biologics S.A.
GLOBAL GENE THERAPY MARKET, BY INDICATION
Acute Lymphoblastic Leukemia (ALL)
Inherited Retinal Disease
Large B-cell Lymphoma
Head & Neck Squamous Cell Carcinoma
Peripheral Arterial Disease
Spinal Muscular Atrophy (SMA)
GLOBAL GENE THERAPY MARKET, BY VECTOR TYPE
Retrovirus & gamma Retrovirus
Modified Herpes Simplex Virus
Non-viral Plasmid Vector
GLOBAL GENE THERAPY MARKET, BY REGION
Rest of Europe
Rest of APAC
Rest of LATAM
The Middle East and Africa
United Arab Emirates
Rest of MEA
List of Tables
List of Figures